SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Global Stem Cell Umbilical Cord Blood (UCB) Market - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast to 2020

DUBLIN, April 2, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/7vkq8r/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast to 2020" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020. The storage service market was valued at $7.4 billion in 2013. 

"Cord blood stem cell application is increasing at faster rate than other stem cell techniques because of its efficient and cost effective treatment process. Cord blood is assisting the healthcare industry to discover novel therapies on chronic diseases. UCB stem cell market is evidencing significant growth due to increasing public awareness and government support." state Allied Market Research analyst Debbie Shields and Roshan Deshmukh. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. 

These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. 

However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. 

Key Topics Covered: 

CHAPTER 1 INTRODUCTION
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET OVERVIEW
CHAPTER 4 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY STORAGE SERVICE
CHAPTER 5 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY THERAPEUTICS
CHAPTER 6 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY APPLICATION
CHAPTER 7 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY GEOGRAPHY
CHAPTER 8 COMPANY PROFILES

Companies Mentioned:

  • Advanced Cell Technology
  • Athersys
  • California Stem Cell
  • Cytori Therapeutics
  • Geron Corporation
  • Mesoblast Limited
  • NeoStem
  • Opexa Therapeutics
  • Osiris Therapeutics
  • Pluristem Therapeutics

For more information visit http://www.researchandmarkets.com/research/7vkq8r/global_stem_cell

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.